Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3179) 3179
Newsletter (351) 351
Book Chapter (99) 99
Newspaper Article (94) 94
Magazine Article (21) 21
Conference Proceeding (7) 7
Publication (6) 6
Streaming Video (4) 4
Transcript (4) 4
Web Resource (4) 4
Dissertation (3) 3
Book Review (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
denosumab (3415) 3415
science & technology (1858) 1858
life sciences & biomedicine (1840) 1840
humans (1777) 1777
osteoporosis (1344) 1344
female (950) 950
bone density conservation agents - therapeutic use (738) 738
male (654) 654
bisphosphonates (618) 618
research (585) 585
care and treatment (526) 526
aged (521) 521
fractures (518) 518
middle aged (505) 505
endocrinology & metabolism (476) 476
oncology (468) 468
denosumab - therapeutic use (453) 453
drug therapy (428) 428
diphosphonates - therapeutic use (423) 423
metastasis (414) 414
bones (405) 405
antibodies, monoclonal, humanized (391) 391
zoledronic acid (387) 387
health aspects (383) 383
bone density conservation agents - adverse effects (369) 369
cancer (364) 364
risk factors (358) 358
osteoporosis - drug therapy (354) 354
bone neoplasms - secondary (338) 338
antibodies, monoclonal - therapeutic use (336) 336
bone neoplasms - drug therapy (322) 322
orthopedics (318) 318
osteoporosis, postmenopausal - drug therapy (309) 309
medicine & public health (303) 303
postmenopausal women (297) 297
antibodies, monoclonal, humanized - therapeutic use (290) 290
bone density - drug effects (287) 287
immunotherapy (284) 284
analysis (282) 282
breast cancer (276) 276
treatment outcome (273) 273
prostate cancer (272) 272
bone mineral density (251) 251
bone density (244) 244
patients (235) 235
medical research (233) 233
rank ligand - antagonists & inhibitors (232) 232
aged, 80 and over (228) 228
denosumab - adverse effects (224) 224
medicine, experimental (219) 219
bone density conservation agents - administration & dosage (218) 218
adult (215) 215
tumors (215) 215
surgery (212) 212
rankl (200) 200
bisphosphonate (199) 199
pharmacology & pharmacy (196) 196
rheumatology (192) 192
density (190) 190
dosage and administration (186) 186
rank ligand - therapeutic use (186) 186
animals (180) 180
biological and medical sciences (180) 180
prevention (178) 178
abridged index medicus (174) 174
general & internal medicine (173) 173
medicine, general & internal (169) 169
bone metastases (168) 168
phosphonates (167) 167
diphosphonates - adverse effects (166) 166
denosumab - administration & dosage (164) 164
vitamin d (164) 164
medical sciences (162) 162
endocrinology (160) 160
teriparatide (159) 159
monoclonal antibodies (158) 158
clinical trials (148) 148
complications and side effects (148) 148
osteoporotic fractures - prevention & control (147) 147
alendronate (145) 145
necrosis (145) 145
osteonecrosis (142) 142
dentistry (140) 140
imidazoles - therapeutic use (138) 138
review (138) 138
women (131) 131
retrospective studies (129) 129
parathyroid hormone (128) 128
bone density conservation agents - pharmacology (126) 126
chemotherapy (126) 126
medicine (120) 120
bone remodeling - drug effects (116) 116
antibodies, monoclonal, humanized - adverse effects (115) 115
pain (115) 115
development and progression (114) 114
bone metastasis (113) 113
usage (113) 113
antineoplastic agents - therapeutic use (111) 111
fractures, bone - prevention & control (110) 110
cancer therapies (109) 109
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3476) 3476
Japanese (104) 104
German (80) 80
French (71) 71
Spanish (42) 42
Russian (24) 24
Czech (17) 17
Italian (16) 16
Chinese (12) 12
Danish (9) 9
Hungarian (9) 9
Portuguese (8) 8
Polish (6) 6
Dutch (5) 5
Slovak (4) 4
Korean (3) 3
Swedish (3) 3
Croatian (2) 2
Slovenian (2) 2
Belarusian (1) 1
Finnish (1) 1
Indonesian (1) 1
Norwegian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Overall survival in female Medicare beneficiaries with early stage breast cancer receiving bisphosphonates or denosumab
by Herrera Pena, Raul A and Lei, Xiudong and Chavez-MacGregor, Mariana and Zhao, Hui and Giordano, Sharon Hermes and Suarez-Almazor, Maria E
Journal of clinical oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. 530 - 530
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Osteonecrosis of jaw (ONJ) after antiresorptive treatment (bisphosphonates, denosumab) of cancer-treatment induced bone loss (CTIBL): a negligible risk?
by Gambino, A and Cabras, M and Fusco, V and Bertetto, O and De Martino, I and Alessio, M and Numico, G
Annals of oncology, ISSN 0923-7534, 10/2017, Volume 28, pp. vi96 - vi96
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Medication-Related Osteonecrosis of JAW (MR-ONJ) After Bisphosphonates, Denosumab and other Drugs in Advanced Cancer Patients: Recent Experience Data from Rete Oncologica Piemonte – Valle D’aosta (North-Western Italy Cancer Network)
by Fusco, V and Cabras, M and Gambino, A and Bertetto, O and Numico, G and De Martino, I and Alessio, M and Marinella, M
Annals of oncology, ISSN 0923-7534, 10/2017, Volume 28, pp. vi90 - vi90
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Cost-Utility Analysis of Denosumab Versus Alendronate For Postmenopausal Osteoporosis In South Korea
by Bae, G and Kwon, H and An, J and Park, J
Value in health, ISSN 1098-3015, 09/2018, Volume 21, p. S82
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Efficacy and safety of denosumab from a phase III, randomized, active-controlled study compared with zoledronic acid in patients of Asian ancestry with bone metastases from solid tumors
by Jiang, Zefei and Shao, Zhimin and Zhang, Qingyuan and Yao, Yang and He, Jianxing and Liao, Wangjun and Qin, Shukui and Cheng, Ying and Xu, Yanmei and Dong, Jie and Zhang, Li
Journal of clinical oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. 10116 - 10116
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Osteonecrosis of jaw (ONJ) with and without bone exposure in patients receiving antiangiogenic agents (+/- bisphosphonates or denosumab)
by Fusco, V and Fasciolo, A and Gaino, R and Tartara, D and De Martino, I and Alessio, M and Benzi, L and Rapetti, M and Cammarata, R and Caravaggio, E and Vincenti, M and Gugliemini, P
Annals of oncology, ISSN 0923-7534, 10/2015, Volume 26, p. vi117
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Antiresorptive agents for the prevention of fractures after spinal cord injury
by Montenegro, Constanza and Soto, Claudio and Rada, Gabriel
Cochrane database of systematic reviews, ISSN 1465-1858, 12/2013, Volume 2013, Issue 12
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials
by Lipton, Allan and Saad, Fred and Van Poznak, Catherine H and Brown, Janet Elizabeth and Stopeck, Alison and Fizazi, Karim and Henry, David H and Shore, Neal D and Diel, Ingo J and Tonkin, Katia Sonia and De Boer, Richard H and Wang, Huei and Braun, Ada H
Journal of clinical oncology, ISSN 0732-183X, 05/2013, Volume 31, Issue 15_suppl, pp. 9640 - 9640
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Reply to V. Fusco et al
by Stopeck, Alison T and Lipton, Allan and Body, Jean-Jacques and Steger, Guenther G and Tonkin, Katia and De Boer, Richard H and Lichinitser, Mikhail and Fujiwara, Yasuhiro and Yardley, Denise A and Viniegra, María and Fan, Michelle and Jiang, Qi and Dansey, Roger and Jun, Susie and Braun, Ada
Journal of clinical oncology, ISSN 0732-183X, 06/2011, Volume 29, Issue 17, pp. e523 - e524
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Cancer-related pain management in clinical oncology
by Cipta, Andre M and Pietras, Christopher J and Weiss, Timothy E and Strouse, Tomas B
The Journal of community and supportive oncology, ISSN 2330-7749, 10/2015, Volume 13, Issue 10, pp. 347 - 355
Journal Article
Details down arrow
11. Full Text Osteoclast inhibitors to prevent bone metastases in men with high-risk, nonmetastatic prostate cancer: A systematic review and meta-Analysis
by Hayes, Aimee R and Brungs, Daniel and Pavlakis, Nick
PloS one, 01/2018, Volume 13, Issue 1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text The PPAR-[gamma] antagonist T007 inhibits RANKL-induced osteoclastogenesis and counteracts OVX-induced bone loss in mice
by Li, Xiang and Ning, Lei and Ma, Jianjun and Xie, Ziang and Zhao, Xiangde and Wang, Gangliang and Wan, Xinyu and Qiu, Pengcheng and Yao, Teng and Wang, Haoming and Fan, Shunwu and Wan, Shuanglin
Cell communication and signaling, ISSN 1478-811X, 10/2019, Volume 17, Issue 1
Osteoporosis | Denosumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text National Kidney Foundation 2018 Spring Clinical Meeting Abstracts April 10-14, 2018
American journal of kidney diseases, ISSN 0272-6386, 04/2018, Volume 71, Issue 4, pp. 502 - 515
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study
by Hadji, P and Papaioannou, N and Gielen, E and Tepie, M.F and Zhang, E and Frieling, I and Geusens, P and Makras, P and Resch, H and Möller, G and Kalouche-Khalil, L and Fahrleitner-Pammer, A
Osteoporosis international, ISSN 0937-941X, 10/2015, Volume 26, Issue 10, pp. 2479 - 2489
DIAGNOSIS | TURNOVER | Compliance | BONE-MINERAL DENSITY | EFFICACY | FRACTURE RATES | ORAL IBANDRONATE | RISK | Denosumab | ALENDRONATE | CARE | Adherence | Persistence | Osteoporosis | REAL-WORLD ADHERENCE | Non-interventional study | Medicine & Public Health | Orthopedics | Rheumatology | Endocrinology | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Medication Adherence - statistics & numerical data | Osteoporosis, Postmenopausal - epidemiology | Prospective Studies | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Comorbidity | Humans | Middle Aged | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Europe - epidemiology | Bone Density Conservation Agents - administration & dosage | Denosumab - adverse effects | Medicine - statistics & numerical data | Osteoporosis, Postmenopausal - drug therapy | Denosumab - therapeutic use | Denosumab - administration & dosage | Injections, Subcutaneous | Aged, 80 and over | Female | Aged | Osteoporotic Fractures - epidemiology | Osteoporosis, Postmenopausal - psychology | Analysis | Postmenopausal women | Dosage and administration | Drug therapy | Health aspects | Patient compliance | Prescription drugs | Menopause | Health behavior | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Paget's disease of bone revisited: The changing Indian scenario
by Cherian, Kripa and Kapoor, Nitin and Paul, Thomas
Indian journal of endocrinology and metabolism, ISSN 2230-8210, 7/2020, Volume 24, Issue 4, pp. 293 - 294
Alendronate | Denosumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text RANKL as a target for the treatment of osteoporosis
by Matsumoto, Toshio and Endo, Itsuro
Journal of bone and mineral metabolism, ISSN 0914-8779, 01/2021, Volume 39, Issue 1, pp. 91 - 105
Endocrinology & Metabolism | Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Bone and Bones - pathology | Animals | RANK Ligand - metabolism | Humans | Denosumab - pharmacokinetics | Osteoporosis - drug therapy | Clinical Trials as Topic | Denosumab - adverse effects | Denosumab - pharmacology | Molecular Targeted Therapy | Bone and Bones - drug effects | Denosumab - therapeutic use | Prevention | Osteoporosis | Medical research | Biological products | Corticosteroids | Medicine, Experimental | Rankings | Drug therapy | Denosumab | NF-κB protein | Pharmacodynamics | Glucocorticoids | Bone turnover | Bone resorption | Bone growth | Fractures | Bone mass | Osteoclasts | TRANCE protein | Bone strength | Osteogenesis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects
by Zhang, Hong and Li, Cuiyun and Liu, Jingrui and Wu, Min and Li, Xiaojiao and Zhu, Xiaoxue and Li, Qianqian and Wang, Boguang and Mao, Yanhong and Ding, Yanhua and Jin, Qinglong
Expert opinion on investigational drugs, ISSN 1354-3784, 02/2021, Volume 30, Issue 2, pp. 185 - 192
pharmacokinetics | Inter-subject variability | immunogenicity | denosumab | biosimilar | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Bone Density Conservation Agents - pharmacokinetics | Biosimilar Pharmaceuticals - administration & dosage | Bone Density Conservation Agents - adverse effects | Double-Blind Method | Humans | Middle Aged | Male | Bone Density Conservation Agents - administration & dosage | Denosumab - adverse effects | Healthy Volunteers | Biosimilar Pharmaceuticals - adverse effects | Denosumab - administration & dosage | China | Injections, Subcutaneous | Patient Safety | Biosimilar Pharmaceuticals - pharmacokinetics | Denosumab - pharmacokinetics | Adult | Female | Therapeutic Equivalency | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Observations following discontinuation of long-term denosumab therapy
by McClung, M.R and Wagman, R.B and Miller, P.D and Wang, A and Lewiecki, E.M
Osteoporosis international, ISSN 0937-941X, 05/2017, Volume 28, Issue 5, pp. 1723 - 1732
Osteoporosis | Discontinuation | Denosumab | Treatment cessation | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Bone Density Conservation Agents - adverse effects | Drug Administration Schedule | Humans | Middle Aged | Osteoporotic Fractures - prevention & control | Osteoporosis, Postmenopausal - complications | Bone Density Conservation Agents - administration & dosage | Osteoporotic Fractures - etiology | Denosumab - adverse effects | Withholding Treatment | Osteoporosis, Postmenopausal - drug therapy | Bone Density - drug effects | Denosumab - administration & dosage | Hip Joint - physiopathology | Female | Osteoporosis, Postmenopausal - physiopathology | Aged | Osteoporotic Fractures - physiopathology | Lumbar Vertebrae - physiopathology | Vertebrae | Fractures | Spine (lumbar) | Bone mineral density | Management | Bone loss | Hip | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Significant bone loss after stopping long-term denosumab treatment: a post FREEDOM study
by Zanchetta, M B and Zanchetta, M B and Boailchuk, J and Boailchuk, J and Massari, F and Massari, F and Silveira, F and Silveira, F and Bogado, C and Bogado, C and Zanchetta, J R and Zanchetta, J R
Osteoporosis international, ISSN 0937-941X, 1/2018, Volume 29, Issue 1, pp. 41 - 47
Osteoporosis | Vertebral fractures | Medicine & Public Health | Orthopedics | Rheumatology | Post-denosumab | Bone turnover | Denosumab | Endocrinology | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Drug Administration Schedule | Follow-Up Studies | Humans | Osteoporotic Fractures - prevention & control | Bone Density Conservation Agents - therapeutic use | Bone Density Conservation Agents - administration & dosage | Withholding Treatment | Absorptiometry, Photon | Osteoporosis, Postmenopausal - drug therapy | Denosumab - therapeutic use | Bone Density - drug effects | Denosumab - administration & dosage | Deprescriptions | Hip Joint - physiopathology | Aged, 80 and over | Female | Femur Neck - physiopathology | Osteoporosis, Postmenopausal - physiopathology | Aged | Osteoporotic Fractures - physiopathology | Lumbar Vertebrae - physiopathology | Postmenopausal women | Femur | Vertebrae | Osteocalcin | Spine | Bisphosphonates | Hip | Post-menopause | Wrist | Fractures | Vitamin D | Collagen | Bone mineral density | Bone (long) | Bone matrix | TRANCE protein | Bone loss | Geriatrics | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Anti-receptor activator of nuclear factor κB ligand antibody treatment increases osteoclastogenesis-promoting IL-8 in patients with rheumatoid arthritis
by Morita, Takayoshi and Shima, Yoshihito and Fujimoto, Kosuke and Tsuboi, Hideki and Saeki, Yukihiko and Narazaki, Masashi and Ogata, Atsushi and Kumanogoh, Atsushi
International immunology, ISSN 0953-8178, 2019, Volume 31, Issue 5, pp. 277 - 285
FK506 | Denosumab | Osteoimmunology RANKL | Osteoclast-like cells | Life Sciences & Biomedicine | Immunology | Science & Technology | Denosumab - immunology | Humans | Middle Aged | Cells, Cultured | Male | Osteogenesis - immunology | Denosumab - therapeutic use | RANK Ligand - immunology | RANK Ligand - antagonists & inhibitors | Arthritis, Rheumatoid - drug therapy | Female | Arthritis, Rheumatoid - immunology | Denosumab - pharmacology | Interleukin-8 - blood | Interleukin-8 - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.